ダウンロード数: 134

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
68_7_217.pdf1.49 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.author大西, 健太ja
dc.contributor.author田中, 宣道ja
dc.contributor.author堀, 俊太ja
dc.contributor.author中井, 靖ja
dc.contributor.author三宅, 牧人ja
dc.contributor.author穴井, 智ja
dc.contributor.author藤本, 清秀ja
dc.contributor.alternativeONISHI, Kentaen
dc.contributor.alternativeTANAKA, Nobumichien
dc.contributor.alternativeHORI, Shuntaen
dc.contributor.alternativeNAKAI, Yasushien
dc.contributor.alternativeMIYAKE, Makitoen
dc.contributor.alternativeANAI, Satoshien
dc.contributor.alternativeFUJIMOTO, Kiyohideen
dc.date.accessioned2022-08-05T01:53:36Z-
dc.date.available2022-08-05T01:53:36Z-
dc.date.issued2022-07-31-
dc.identifier.urihttp://hdl.handle.net/2433/275779-
dc.description本論文の要旨は,第109回日本泌尿器科学会総会で発表を行った.ja
dc.description.abstractSarcopenia is a known predictor of overall survival in several diseases. We investigated the relationship between sarcopenia and outcome of treatment with cabazitaxel (CBZ) for castration-resistant prostate cancer (CRPC) by a retrospective analysis of 37 patients, who were given cabazitaxel at our hospital, from December 2014 to November 2020. The skeletal muscle mass was evaluated using the Psoas Muscle Mass Index (PMI: psoas major muscle area at the level of the third lumber vertebra (cm²)/height x height (m²)) through computed tomography images. The severe sarcopenia group (PMI<4.96) showed lower levels of serum albumin, in comparison with the non-severe sarcopenia group (PMI≥4.96). Multivariate analysis identified PMI (odds ratio=3.7; P=0.023) as an independent factor associated with prostate specific antigen response to CBZ therapy. However, there was no significant difference in the overall survival between the severe and the non-severe sarcopenia groups (P=0.1). Skeletal muscle mass might be closely correlated to the therapeutic response to CBZ, but not to the prognosis of patients with CRPC. Nutritional rehabilitation and exercises targeting sarcopenia for patients with prostate cancer should be considered.en
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.rights許諾条件により本文は2023/08/01に公開ja
dc.subjectCastration-resistant prostate canceren
dc.subjectCabazitaxelen
dc.subjectSarcopeniaen
dc.subject.ndc494.9-
dc.title去勢抵抗性前立腺癌に対するカバジタキセル療法の治療成績とサルコペニアとの関連についての検討ja
dc.title.alternativeThe Relationship between Sarcopenia and Survival after Cabazitaxel Treatment for Castration-Resistant Prostate Canceren
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume68-
dc.identifier.issue7-
dc.identifier.spage217-
dc.identifier.epage225-
dc.textversionpublisher-
dc.sortkey02-
dc.address奈良県立医科大学泌尿器科; JCHO星ヶ丘医療センター泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address奈良県立医科大学泌尿器科ja
dc.address.alternativeThe Department of Urology, Nara Medical University; The Department of Urology, Japan Community Healthcare Organization Hoshigaoka Medical Centeren
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.address.alternativeThe Department of Urology, Nara Medical Universityen
dc.identifier.pmid35924704-
dc.identifier.selfDOI10.14989/ActaUrolJap_68_7_217-
dcterms.accessRightsopen access-
datacite.date.available2023-08-01-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.68 No.7

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。